美股A股
StockGist

Artivion, Inc.

AORTNYSE · Healthcare · Medical - Devices
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
$19.10-1.55%
报价 2026-11-13
市值
$931.9M
EV
$1.34B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -59.5%
$19.10$47.18

筛选结果

pipeline · 2026-11-13
Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool

爆发潜力

2026-11-13
未命中✗ 收入线✗ EPS 线
财年收入倍数EPSPE
FY+22027-121.1x0.19 → 0.14(0.7x)136.4
FY+32028-121.2x0.19 → 0.38(2.0x)50.6

毛利率 62% · TTM 收入 $482M · 基数 EPS 0.19(调整后)

一次性亏损已剔除

电话会信号

辅助标签
Q3 20262026-11-05
扩产需求加速供不应求
指引 维持
信心 4
分析师 3

“NEXUS U.S. launch expected January 2027, with meaningful revenue contribution beginning then and building through the year.”

原文引用(3)
  • 扩产:our focus will remain on expanding manufacturing capacity and building inventory
  • 需求加速:the number of U.S. implants increased in the second quarter, which we believe reflects the impact of our recent PMA approval
  • 供不应求:they've been supply constrained. We've invested, as we've talked on previous calls, significantly in our Austin manufacturing facility

蓝色标签在暴涨研究中略有区分度;悬停查看口径。

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
AORTArtivion, Inc.$931.9M-1.5%+10.8%61.4%–31.8x–
LFSTLifeStance Health Group, Inc.$5.35B-0.5%+22.7%35.4%75.6x36.7x30.5xGARP
LQDALiquidia Corporation$5.17B-1.2%+366.9%92.5%30.2x23.0x70.1x
COGTCogent Biosciences, Inc.$4.97B-2.0%+260.0%0%–––
ITGRInteger Holdings Corporation$4.31B+0.2%-1.7%24.3%34.2x18.0x38.2x
ARDTArdent Health Partners, LLC$2.51B+0.7%+2.0%15.9%17.5x8.4x9.1x
ADUSAddus HomeCare Corporation$2.29B-0.6%+7.1%32.2%20.3x12.9x14.1x
BKDBrookdale Senior Living Inc.$2.19B+2.3%-9.5%28.7%–18.0x151.5x
INSPInspire Medical Systems, Inc.$1.77B+0.9%-5.8%85.5%14.8x22.8x17.1x
同行中位数––+4.6%30.4%25.3x18.0x30.5x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

Metric
2026-09-30
Q3 2026
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
Revenue$123.8M$125.8M$116.3M$116M$113.4M$113M$99M$97.3M
Gross Margin61.4%64%61.5%60.1%65.6%64.7%64.2%63.2%
Operating Margin2.4%-6.7%6.4%6.2%11.1%7.4%2.2%2.7%
Net Income$-7.9M$-13.5M$1.4M$2.4M$6.5M$1.3M$-505,000$-16.5M
Diluted EPS-0.16-0.280.030.050.130.03-0.01-0.39
Operating Cash Flow$-4.6M$-1.3M$1.2M$19.6M$22.3M$15M$-17M$10.1M

研究材料